AstraZeneca PLC’s Tagrisso (osimertinib) is likely to become the standard of care for patients with unresectable locally advanced stage III EGFR-mutant non-small cell lung cancer (NSCLC) who have undergone chemoradiotherapy, based on Phase III data presented at the American Society of Clinical Oncology annual meeting showing an overwhelming benefit on the primary endpoint of progression-free survival (PFS).
ASCO: AstraZeneca Touts LAURA’s Large PFS Benefit In EGFR-Mutant NSCLC
While the study allowed a crossover, and the overall survival benefit did not reach statistical significance, the drug maker sees the PFS benefit from Tagrisso as likely to drive uptake.
More from ASCO
• By
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
• By
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
• By
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
• By
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.